A novel pathway for regulation of glucose‐dependent insulinotropic polypeptide receptor expression in β‐cells
暂无分享,去创建一个
R. Pederson | C. Mcintosh | J. Pospisilik | J. Ehses | N. Pamir | F. Lynn | S. Hinke | S. A. Thompson
[1] C. Heinlein,et al. Repression of Glucagon Gene Transcription by Peroxisome Proliferator-activated Receptor γ through Inhibition of Pax6 Transcriptional Activity* , 2002, The Journal of Biological Chemistry.
[2] D. Hörsch,et al. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. , 2001, Molecular endocrinology.
[3] R. Pederson,et al. A New Pathway for Glucose-dependent Insulinotropic Polypeptide (GIP) Receptor Signaling , 2001, The Journal of Biological Chemistry.
[4] S. Biswal,et al. Inhibition of peroxisome-proliferator-activated receptor (PPAR)α by MK886 , 2001 .
[5] R. Pederson,et al. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. , 2001, Diabetes.
[6] S. Bonner-Weir,et al. beta-cell adaptation to hyperglycemia. , 2001, Diabetes.
[7] M. Prentki,et al. Glucose Down-regulates the Expression of the Peroxisome Proliferator-activated Receptor-α Gene in the Pancreatic β-Cell* , 2000, The Journal of Biological Chemistry.
[8] R. Pederson,et al. Role of glucose in chronic desensitization of isolated rat islets and mouse insulinoma (betaTC-3) cells to glucose-dependent insulinotropic polypeptide. , 2000, The Journal of endocrinology.
[9] M. Prentki,et al. Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. , 2000, Diabetes.
[10] M. Prentki,et al. Glucose down-regulates the expression of the peroxisome proliferator-activated receptor-alpha gene in the pancreatic beta -cell. , 2000, The Journal of biological chemistry.
[11] J. Miyazaki,et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[12] W. Wahli,et al. Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.
[13] S. Seino,et al. PKA‐mediated phosphorylation of the human KATP channel: separate roles of Kir6.2 and SUR1 subunit phosphorylation , 1999, The EMBO journal.
[14] B Staels,et al. A truncated human peroxisome proliferator-activated receptor alpha splice variant with dominant negative activity. , 1999, Molecular endocrinology.
[15] R. Unger,et al. Novel Form of Lipolysis Induced by Leptin* , 1999, The Journal of Biological Chemistry.
[16] M. Wolfe,et al. Effect of GIP and GLP-1 antagonists on insulin release in the rat. , 1999, American journal of physiology. Endocrinology and metabolism.
[17] L. Orci,et al. Regulation of fatty acid homeostasis in cells: novel role of leptin. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[18] C. Kahn,et al. Tissue-Specific Knockout of the Insulin Receptor in Pancreatic β Cells Creates an Insulin Secretory Defect Similar to that in Type 2 Diabetes , 1999, Cell.
[19] S. Walker,et al. Quantitative RT-PCR : Pitfalls and Potential , 1999 .
[20] R. Pederson,et al. Glucose-dependent insulinotropic polypeptide stimulation of lipolysis in differentiated 3T3-L1 cells: wortmannin-sensitive inhibition by insulin. , 1999, Endocrinology.
[21] B. Göke,et al. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. , 1998, The Journal of clinical investigation.
[22] C. Newgard,et al. Role of peroxisome proliferator-activated receptor alpha in disease of pancreatic beta cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[23] J. Holst,et al. The pathogenesis of NIDDM involves a defective expression of the GIP receptor , 1997, Diabetologia.
[24] D. D’Alessio,et al. Peptide Hormone Regulation of Islet Cells , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[25] M. Prentki,et al. Signal transduction mechanisms in nutrient-induced insulin secretion , 1997, Diabetologia.
[26] J. Gromada,et al. Protein Kinase A-Dependent Stimulation of Exocytosis in Mouse Pancreatic β-Cells by Glucose-Dependent Insulinotropic Polypeptide , 1997, Diabetes.
[27] M. Prentki,et al. Fatty Acids Rapidly Induce the Carnitine Palmitoyltransferase I Gene in the Pancreatic β-Cell Line INS-1* , 1997, The Journal of Biological Chemistry.
[28] T. Usdin,et al. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. , 1996, The Journal of clinical investigation.
[29] A. Joyner,et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene , 1996, Nature Medicine.
[30] E. Ah-Sing,et al. Characterization of a Novel Glucose-Responsive Insulin-Secreting Cell Line, BRIN-BD11, Produced by Electrofusion , 1996, Diabetes.
[31] Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP): Effect of a GIP-specific receptor antagonist , 1996, Regulatory Peptides.
[32] J. Brown,et al. GIP receptors and signal-transduction mechanisms. , 1996, Acta physiologica Scandinavica.
[33] J. Brown,et al. Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties. , 1995, Endocrinology.
[34] K. Griffin,et al. A single amino acid change in the mouse peroxisome proliferator-activated receptor alpha alters transcriptional responses to peroxisome proliferators. , 1995, Molecular pharmacology.
[35] R. Pederson,et al. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. , 1995, Endocrinology.
[36] J. Holst,et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.
[37] V. Marks,et al. Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. , 1991, The Journal of endocrinology.
[38] C. Strader,et al. Insulin receptor desensitization correlates with attenuation of tyrosine kinase activity, but not of receptor endocytosis. , 1987, The Biochemical journal.
[39] B. Beck,et al. Gastric inhibitory polypeptide enhancement of the insulin effect on fatty acid incorporation into adipose tissue in the rat , 1983, Regulatory Peptides.
[40] J. Brown,et al. Effect of jejunoileal bypass in the rat on the enteroinsular axis , 1982, Regulatory Peptides.
[41] J. Brown,et al. The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas. , 1976, Endocrinology.
[42] J. Brown,et al. Gastric Inhibitory Polypeptide: Its Physiologic Release and Insulinotropic Action in the Dog , 1975, Diabetes.
[43] J. Brown,et al. The insulinotropic action of gastric inhibitory polypeptide. , 1975, Canadian journal of physiology and pharmacology.